Eshhar Z - Search Results

1

Photodynamic therapy of established prostatic adenocarcinoma with TOOKAD: a biphasic apparent diffusion coefficient change as potential early MRI response marker.

Plaks V, Koudinova N, Nevo U, Pinthus JH, Kanety H, Eshhar Z, Ramon J, Scherz A, Neeman M, Salomon Y. Plaks V, et al. Among authors: eshhar z. Neoplasia. 2004 May-Jun;6(3):224-33. doi: 10.1593/neo.3352. Neoplasia. 2004. PMID: 15153334 Free PMC article.

2

Photodynamic therapy with Pd-Bacteriopheophorbide (TOOKAD): successful in vivo treatment of human prostatic small cell carcinoma xenografts.

Koudinova NV, Pinthus JH, Brandis A, Brenner O, Bendel P, Ramon J, Eshhar Z, Scherz A, Salomon Y. Koudinova NV, et al. Among authors: eshhar z. Int J Cancer. 2003 May 10;104(6):782-9. doi: 10.1002/ijc.11002. Int J Cancer. 2003. PMID: 12640688

3

Immuno-gene therapy of established prostate tumors using chimeric receptor-redirected human lymphocytes.

Pinthus JH, Waks T, Kaufman-Francis K, Schindler DG, Harmelin A, Kanety H, Ramon J, Eshhar Z. Pinthus JH, et al. Among authors: eshhar z. Cancer Res. 2003 May 15;63(10):2470-6. Cancer Res. 2003. PMID: 12750268

4

Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes.

Pinthus JH, Waks T, Malina V, Kaufman-Francis K, Harmelin A, Aizenberg I, Kanety H, Ramon J, Eshhar Z. Pinthus JH, et al. Among authors: eshhar z. J Clin Invest. 2004 Dec;114(12):1774-81. doi: 10.1172/JCI22284. J Clin Invest. 2004. PMID: 15599402 Free PMC article.

5

WISH-PC2: a unique xenograft model of human prostatic small cell carcinoma.

Pinthus JH, Waks T, Schindler DG, Harmelin A, Said JW, Belldegrun A, Ramon J, Eshhar Z. Pinthus JH, et al. Among authors: eshhar z. Cancer Res. 2000 Dec 1;60(23):6563-7. Cancer Res. 2000. PMID: 11118033

6

Redirecting immune cells against bone metastases: Immunotherapy of prostate cancer metastases using genetically programmed immune effector cells.

Eshhar Z, Waks T, Pinthus J. Eshhar Z, et al. Discov Med. 2005 Jun;5(27):259-64. Discov Med. 2005. PMID: 20704885 Free article.

7

Growth inhibition of prostate cancer xenografts by halofuginone.

Gavish Z, Pinthus JH, Barak V, Ramon J, Nagler A, Eshhar Z, Pines M. Gavish Z, et al. Among authors: eshhar z. Prostate. 2002 May 1;51(2):73-83. doi: 10.1002/pros.10059. Prostate. 2002. PMID: 11948962

8

ErbB2 is a tumor associated antigen and a suitable therapeutic target in Wilms tumor.

Pinthus JH, Fridman E, Dekel B, Goldberg I, Kaufman-Francis K, Eshhar Z, Harmelin A, Rechavi G, Mor O, Ramon J, Mor Y. Pinthus JH, et al. Among authors: eshhar z. J Urol. 2004 Oct;172(4 Pt 2):1644-8. doi: 10.1097/01.ju.0000140139.91993.a0. J Urol. 2004. PMID: 15371781

9

Multiple genes in human 20q13 chromosomal region are involved in an advanced prostate cancer xenograft.

Bar-Shira A, Pinthus JH, Rozovsky U, Goldstein M, Sellers WR, Yaron Y, Eshhar Z, Orr-Urtreger A. Bar-Shira A, et al. Among authors: eshhar z. Cancer Res. 2002 Dec 1;62(23):6803-7. Cancer Res. 2002. PMID: 12460888

10

Irradiation enhances the metastatic potential of prostatic small cell carcinoma xenografts.

Agemy L, Harmelin A, Waks T, Leibovitch I, Rabin T, Pfeffer MR, Eshhar Z. Agemy L, et al. Among authors: eshhar z. Prostate. 2008 Apr 1;68(5):530-9. doi: 10.1002/pros.20702. Prostate. 2008. PMID: 18247403

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

169 results

Search Page

Filters